阿帕他胺治疗非转移性去势抵抗性前列腺癌患者的真实世界前列腺特异性抗原反应与治疗依从性
本研究利用美国63家泌尿外科诊所的电子病历数据,纳入193例接受阿帕他胺治疗的非转移性去势抵抗性前列腺癌(nmCRPC)患者,描述整体及按种族分层(黑人33例、非黑人138例)的前列腺特异性抗原(PSA)反应与治疗依从性。结果显示整体12个月PSA反应率为86.0%,黑人93.1%,非黑人85.9%;平均随访期间依从率整体93.6%,黑人90.1%,非黑人94.5%。
要点
- 阿帕他胺治疗nmCRPC的12个月PSA反应率整体为86.0%。
- 黑人患者12个月PSA反应率为93.1%,非黑人患者为85.9%。
- 平均随访期间阿帕他胺依从率整体为93.6%,黑人90.1%,非黑人94.5%。
核心结论
- 真实世界研究显示阿帕他胺治疗nmCRPC患者PSA反应稳健,与临床试验数据一致。
- 黑人与非黑人患者均表现出高治疗依从性。
研究设计与样本
- 本研究为基于美国63家泌尿外科诊所电子医疗记录的真实世界研究。
- 纳入接受阿帕他胺治疗且至少2次处方续药、既往前列腺癌管理≥12个月的非转移性去势抵抗性前列腺癌(nmCRPC)患者。
- 随访从阿帕他胺起始至更换其他抗肿瘤治疗、死亡或数据可用截止(2019年10月4日)。
- 共纳入193例nmCRPC患者,其中黑人33例(17.1%),非黑人138例(71.5%),其余种族背景未知。
主要发现
- 整体、黑人和非黑人队列的平均基线PSA水平分别为7.0 ng/mL、10.5 ng/mL和5.6 ng/mL。
- 随访12个月时,整体、黑人和非黑人队列的PSA反应率(较基线PSA下降≥50%)分别为86.0%、93.1%和85.9%。
- 平均随访期分别为333天、352天和326天时,整体、黑人和非黑人队列的依从率分别为93.6%、90.1%和94.5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe prostate-specific antigen (PSA) response and treatment adherence, overall and stratified by race, for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide. METHODS: Electronic medical records representing 63 urology practices from the United States were used to conduct this study. Patients with ≥2 apalutamide prescription fills and ≥12 months of prior prostate cancer management were identified. Patients were followed from apalutamide initiation until a switch to another antineoplastic treatment, death, or end of data availability (October 4, 2019). PSA response (≥50% decline from baseline PSA) and apalutamide adherence rates are described for the overall nmCRPC population treated and also stratified by race (Black and non-Black cohorts). RESULTS: Overall, 193 patients with nmCRPC were initiated on apalutamide. Thirty-three patients were Black (17.1%), 138 were non-Black (71.5%), and the remaining had an unknown racial background. The mean baseline PSA level for the overall, Black, and non-Black cohorts, was 7.0 ng/mL, 10.5 ng/mL, and 5.6 ng/mL, respectively. At 12 months of follow-up, PSA response was 86.0%, 93.1%, and 85.9% for the overall, Black, and non-Black cohorts, respectively. During a mean follow-up period of 333 days, 352 days, and 326 days, adherence was 93.6%, 90.1%, and 94.5% for the overall, Black and non-Black cohorts, respectively. CONCLUSION: This real-world study of patients with nmCRPC initiated on apalutamide showed that PSA response was robust and consistent with clinical trial data. Moreover, both Black and non-Black patients demonstrated high treatment adherence.
引用
- Lowentritt B, Brown G, Pilon D, et al. Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer. Urology. 2022. PMID: 35318045. doi:10.1016/j.urology.2022.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。